within Pharmacolibrary.Drugs.ATC.G;

model G02CB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0002,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G02CB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metergoline is an ergot-derived drug acting as a serotonergic antagonist with some dopaminergic agonist properties. It has been used primarily for the treatment of hyperprolactinemia and disorders related to excess prolactin secretion (such as pituitary adenomas), and occasionally off-label for other conditions. It is rarely used in contemporary clinical practice due to the development of newer agents and concerns about side effects.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models or comprehensive parameters for metergoline in humans have been identified in scientific literature. Estimates below are based on data from related ergot derivatives and general pharmacokinetic principles.</p><h4>References</h4><ol><li><p>Martini, A, et al., &amp; Tamassia, V (1983). Pharmacokinetics and bioavailability of metergoline in healthy volunteers after single i.v. and oral administration. <i>International journal of clinical pharmacology research</i> 3(1) 27–34. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6679505/&quot;>https://pubmed.ncbi.nlm.nih.gov/6679505</a></p></li><li><p>Pigott, TA, et al., &amp; Murphy, DL (1991). Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. <i>Biological psychiatry</i> 29(5) 418–426. DOI:<a href=&quot;https://doi.org/10.1016/0006-3223(91)90264-m&quot;>10.1016/0006-3223(91)90264-m</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2018816/&quot;>https://pubmed.ncbi.nlm.nih.gov/2018816</a></p></li><li><p>Kahn, RS, et al., &amp; van Praag, HM (1990). Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. <i>Psychiatry research</i> 33(2) 189–198. DOI:<a href=&quot;https://doi.org/10.1016/0165-1781(90)90073-e&quot;>10.1016/0165-1781(90)90073-e</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2243896/&quot;>https://pubmed.ncbi.nlm.nih.gov/2243896</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G02CB05;
